Академический Документы
Профессиональный Документы
Культура Документы
com
PHARMA AI SUMMIT
HOW WILL ARTIFICIAL INTELLIGENCE
IMPACT THE PHARMACEUTICAL INDUSTRY?
• Understanding the role of artificial intelligence • Increasing Diversity in Peptide Discovery Us-
in the pharmaceutical industry ing Artificial Intelligence
• Showcasing the Utility of AI in early stages • Adjusting pharmaceutical business models to
of R&D to Prove This Disruptive Technology’s incorporate AI technologies
Validity • AI in Pharma and Drug Discovery Industry
• Introduction to AI applied to chemistry Landscape Networks and New Chemical
• How a combination of artificial intelligence, Entities: Application of Network-driven Drug
physics, and chemistry is accelerating drug Discovery (NDD) in Lead Generation
discovery: a case study • Drug discovery, strategic thinking and the
• AI and the clinical trial design and optimiza- Centaur Chemist
tion opportunities • Modernising the data platform and innovation
• Predicting clinical trial results using deep • AI linked with IoT enable “smart” Digital as-
learning and electronic health records sistants opening new possibilities for Drug
• AI as a journey, not a destination: a learning Development
process
www.globalbsg.com
speakers
Chairperson
Yide Alan Jiang Don Van Dyke Willem Van Hoorn Qi Tang
Chief Strategy Officer at XTalPi Chief Operating Officer at Chief Decision Scientist at Associate Director of Digital
Cloud Pharmaceuticals Exscientia and Data Sciences at Sanofi
Amit Michaeli Nicolas Do Huu & Quentin Dmitry Kaminskiy Murat Tunaboylu
Founder and Chief Technology Perron General Partner at Deep Co-Founder, Director
Officer at Pepticom Co-Founder and Chief Knowledge Ventures at Antiverse
Technology Officer, Co-
Founder and Chief Strategy
Office at Iktos
09:20 Case Study | Showcasing the Utility of AI in early stages of R&D to Prove This Disruptive
Technology’s Validity
• Developing validated methods to showcase applicability of AI platforms
• Building a “disease-profile” and harnessing multi-object optimization tools to design best
candidates
• Matching AI performance to human decision making to demonstrate the utility of AI
platforms
Don Van Dyke | Chief Operating Officer | Cloud Pharmaceutical
12:00 Case Study | C-Level AI Strategy and Technology for Drug Development
• Elements of an AI strategy
• How to accelerate drug development with AI
• AI case study- Quantitative Systems Pharmacology (QSP)
• AI use cases & business outcomes
• AI technology alternatives
Larry Pickett | Former CIO at Purdue Pharma, current CEO at RxDataScience | RxDataScience
13:50 Case Study | Predicting clinical trial results using deep learning and electronic health
records
• Predicting Phase 3 clinical trial results is a critical step of Go/No-Go decision making and
Phase 3 trial design optimization.
• We proposed a framework consisted of three models, an enrolment model, an individual
trough concentration (Ctrough) model and an individual treatment effect model combined
together to predict Phase 3 trial results using deep learning methods.
• A successful case study will be presented.
Qi Tang | Associate Director of Digital and Data Sciences | Sanofi
www.globalbsg.com
14:30 Case Study | AI and the clinical trial design and optimization opportunities
• Challenges in trial design, and where AI can help
• A framework to incorporate AI into design consideration
Pingping NI | Director, Head of Statistics and Programming | Mundipharma Research Ltd
15:40 Case Study | Networks and New Chemical Entities: Application of Network-driven Drug
Discovery (NDD) in Lead Generation
• etwork-driven Drug Discovery (NDD) platform and process
N
• Applying data augmentation to NCE discovery
• Identifying and optimising unique NCEs in Immuno-oncology
Dr. Sree Vadlamudi | Business Development & Programme Manager | E-Therapeutics
09:00 Case Study | How a combination of artificial intelligence, physics, and chemistry is
accelerating drug discovery: a case study
• Effectively harnessing HPC cloud resources for drug discovery
• How AI-powered crystal structure prediction can disrupt the pharmaceutical industry
• Protecting data while leveraging shared, cloud-based HPC resources
• How highly accurate computations can help companies save money, save time, and lower
risk across all phases of drug development
Yide Alan Jiang | Chief Strategy Officer | XTalPi
09:40 Case Study | Drug discovery, strategic thinking and the Centaur Chemist
• Trajectory of hit to candidate is the most expensive part of drug discovery
• Exscientia has successfully combined AI tech with human strategic thinking into the
Centaur ChemistTM
• The Centaur ChemistTM has delivered multiple clinical candidates in less than a year
Willem Van Hoorn | Chief Decision Scientist | Exscientia
10:20 Case Study | Increasing Diversity in Peptide Discovery Using Artificial Intelligence
• The chemical space challenge in peptide discovery, and the method to address it.
• Example of AI discovered bi-specific cyclic peptides for immune modulation.
• Increasing diversity via incorporation of non-natural sub units.
• Examples of effects in Immune modulation and ion channel inhibition projects.
• The future market impacts of AI discovery.
Amit Michaeli | Founder and Chief Technology Office | Pepticom
11:30 Case Study | The importance of predictive analytics to drug time and success rates
• Machine learning is applied to identify paths and time to approval for drug development
programs
• Predictions are generated for each drug development project considering the impact of
each aspect of the project
• An expansive set of historical and current data can be pulled into the model
• Results are based on quantifiable, data-driven evidence derived from extensive data
preparation and statistical modelling.
Ketan Patel | Product Director- Portfolio, Licensing and Clinical | Clarivate Analytics
www.globalbsg.com
13:50
Case Study | AI in Pharma and Drug Discovery Industry Landscape
• I-companies, Investment Funds, Pharma corporations, IT and Tech corporations
A
• Industry Technological and Financial forecasting for 2019-2020
Dmitry Kaminskiy | General Partner | Deep Knowledge Ventures
14:30 Case Study | AI linked with IoT enable “smart” Digital assistants opening new
possibilities for Drug Development
• I ntegration of IoT and AI technologies into a patient-centric digital platform
• New approaches to trial execution
• New generation of pharma products toward mHealth.
Isabelle de Zegher | Founder | BeeLoba
16:10 Case Study | Pharma marketing challenges and how AI solutions can help
• ollective intelligence and possible initiatives for marketing
C
• Solutions for analysis, planning, execution- how to address key needs along the patient
pathway
• How to drive an effective implementation of AI solutions (driving culture, C-level
endorsements)
Alessandro Forlin | Worldwide Associate Brand Director | Novartis Pharma AG
BIOGRAPHIES
Entrepreneurial Board Director, Co-founder, Executive, Industrial Don Van Dyke is Chief Operating Officer at Cloud Pharmaceuticals. In
advisor and Investor his early career, he held increasingly responsible general
Dr. Jiang as Chief Strategy Officer, Board Director of XtalPi, bears management, business development, and executive positions at
primary responsibility for the company’s strategy development American Hospital Supply, Dade Diagnostics, Eastman Kodak and
including identification of growth opportunities, strategic planning Millipore Corporation.
and execution. He joined Xtalpi in 2015 bringing over fifteen years Van Dyke’s work at the intersection of biological science and
of scientific and research management experience. Dr. Jiang computer science began at startup Bio Image Corporation. The
was previously the director of Asia R&D Strategy of the Sanofi- company became market leader in image-based genomics and
Genzyme R&D Center and in that capacity, he was responsible for proteomics under his leadership as VP sales, VP worldwide
the development of Genzyme Asia/China R&D strategy and led marketing and sales, general manager, and CEO.
cross-functional R&D external collaborations and projects in Asia. He has had executive roles at Molecular Mining Corporation, a
Dr. Jiang received his medical degree and doctorate in molecular life science data mining company and INCOGEN, a Bioinformatics
biology followed by post-doctoral research in hematology and company and has advised more than a dozen start-ups and
oncology at Brigham & Women’s Hospital, Harvard Medical School. government agencies.
Willem van Hoorn gained a MSc in Chemical Engineering and a Dr. Tang graduated from University of Wisconsin with PhD in
PhD in computational chemistry at the University of Twente, the statistics in 2010 and has eight years plus of clinical phase drug
Netherlands followed by a postdoc at Yale with Bill Jorgensen. development experience. He has chaired an AI journal club in Sanofi
He subsequently spent a decade at Pfizer Sandwich focusing on since 2017 and has given two short courses on AI and its application
computational techniques for HTS triage and combinatorial library to clinical data analytics in professional conferences. He has
design. This was followed by a position as IT consultant at Accelrys successfully applied AI methods to prediction of individual patient’s
(now Biovia) assisting a range of clients from small biotech to big PK concentration and efficacy and safety outcomes and made
pharma. Since 2013 he is pursuing his long term interest of applying AI explainable by opening the black box using classification and
computer algorithms to drug discovery at Exscientia regression trees, a classical machine learning method. Provisional
patents have been filed for some of his work in application of AI to
Pingping NI the medical field.
Director, Head of Statistics and
Rosangela Sanches
Programming at Mundipharma
South America IT Data & Analytics
Research Ltd
Lead at Bayer
Raymond Hounon
Data & Artificial Intelligence
Business Manager at Microsoft
Isabelle de Zegher, MD, MS, is Founder of BeeLoba, focusing on
patient data sharing solutions. She used to be Vice President,
Integrated Solutions at PAREXEL Informatics, focusing on Big
Data, Data Standards, AI and digital solutions. She worked for 10
years at PAREXEL and 14 years in pharma clinical development
including Novartis, UCB and Cap Gemini Life Sciences consulting.
Before that she worked for 10 years in Health Care IT at Cap
Gemini and in a Belgium SME. She has extensive experience in
health information technology, data standards, data integration,
semantic interoperability and application of AI in clinical research.
She chaired the EFPIA task force on EHR integration and served on
the CDISC Board of Directors for 3 years. She co-chaired the PhUSE
- FDA CSS working group on Emerging technology and served as
chair or co-chair in many conferences.
www.globalbsg.com
BIOGRAPHIES
Nicolas Do Huu
Amit Michaeli
Co-Founder and Chief Technology
Founder and Chief Technology
Officer, Co-Founder and Chief
Officer at Pepticom
Strategy Office at Iktos
“Growing up as the son of a physician during the internet age, I An accomplished data scientist and R&D engineer with proven
felt a constant frustration at the slow entrance of computational expertise in Deep Learning algorithms with an extensive experience
searches into the pharmaceutical field. While computers aided in machine learning, big data analysis and software optimization
humanity towards reaching unprecedented efficiency in everyday in distributed environments. A swiss army knife profile able to fill
tasks, like purchasing electronics or ordering lunch, it wasn’t quite the gap between state-of-the-art theories and fast and scalable
there where we needed it most – finding cures for diseases! I made solutions with user-friendly interfaces as a bonus.
it my life mission to give computers the ability to discover peptide Murat Tunaboylu
drugs. Together with Prof. Amiram Goldblum and Dr. Immanuel
Co-Founder, Director
Lerner, I founded Pepticom, an A.I. peptide drug discovery platform.
at Antiverse
With discovered active peptides in numerous fields, we are getting
closer than ever to achieving this dream.”
Dmitry Kaminskiy
General Partner at Deep Software Engineer/Bioinformatician with 13 years of professional
Knowledge Ventures experience. Mid-career, he has worked in finance and developed
high-frequency trading systems. After switching to biotech he has
built cell imaging software and lab robots for acceleration of cancer
research and automated Thermo Fisher Scientific’s gene synthesis
Dmitry Kaminskiy is an innovative entrepreneur and investor who workflows. He has co-founded consultancy and biotech companies
is active in the fields of BioTech, FinTech, BlockChain, Artificial Svarlight and Antiverse. Currently, he is developing machine
Intelligence. Kaminskiy is a co-founder and a managing partner learning models at Antiverse to speed up drug discovery.
at Deep Knowledge Ventures, an investment fund focused on
Ketan Patel
DeepTech and advanced science projects.
Product Director- Portfolio,
Dmitry is a frequent speaker on the topics of AI and Longevity.
Licensing and Clinical at Clarivate
During the last year he spoke at conferences organized in London
by The Economist “Aging Societies and The Business of Longevity”, Analytics
Financial Times “Smart Machines vs Smart People”, and at the
Future Finance Forum in Seoul “AI in Finance”, as well as several Ketan’s background spans 15 years of experience working in industry
others at Oxford and Cambridge Universities. at Lilly, Pfizer, Oracle HSGBU and most recently at Astrazeneca.
Dr. Sree Vadlamudi Over the years Ketan has led and worked on data science projects
Business Development & in the industry from early stage drug discovery through to clinical
Programme Manager at development, product launch and medical affairs. More recently
E-Therapeutics he was a Health informatics Director working on Big Health data
(claims, EHRs, digital, genomics etc.) for AZ to optimise clinical trials,
product launch and post-marketing and life cycle management
Sree joined e-therapeutics in 2013 as a Programme Manager to
Larry Pickett
help in the implementation of the network-driven approach to
Former CIO at Purdue Pharma,
drug discovery and was subsequently promoted to the Business
Development and Programme Manager role. He is a medicinal current CEO at RxDataScience at
chemist by training with over 14 years’ experience in the RxDataScience
Biotechnology industry. He has a track record in leading projects
from inception to lead generation and optimisation, and is a named Larry A Pickett, Jr is co-founder and CEO of RxDataScience Inc., a
author on multiple patents and publications. Sree is responsible data science company focused on healthcare and life sciences.
for business development activities to maximize collaborations and He has 30 year’s experience in the pharmaceutical industry in IT
licensing opportunities with bio-pharma organizations, programme in executive roles such as Chief Information Officer for companies
management activities to enable delivery of multiple projects on such as Merck, GSK and Purdue Pharma. Larry earned his BA and
time and within budgets. MBA from the University of North Carolina at Chapel Hill. Larry
Alessandro Forlin enjoys working with his clients to leverage data using AI and ML to
Worldwide Associate Brand improve business results in a predictive and reliable manner.
Director at Novartis Pharma AG Quentin Perron
Co-Founder and Chief Strategy
Officer at Iktos
Alessandro is International marketing leader with over 13 years
of successful strategic and operational pharmaceutical marketing
career at Global, Region and Country level, working in different
therapeutic areas for companies such as Lilly, Menarini and Novo Co-founder and CSO of Iktos, Quentin Perron holds a PhD in organic
Nordisk. More recently he joined Novartis Pharma AG at company chemistry from U. Geneva and a postdoc in total synthesis at UCLA.
headquarter in Basel with the role as WorldWide Associate Brand He is an expert in chemoinformatics. He is the co-inventor of Iktos
Director in the Rheumatology area and actively collaborating with original de novo design algorithm and supervises R&D and project
the Digital Solutions Team. He is passionate about bringing AI delivery.
solutions into pharma marketing and has a foresight view about
how pharma marketing can evolve thanks to AI.
www.globalbsg.com
REGISTRATION FORM
Title: Title:
Name: Name:
Possition: Possition:
Email: Email:
Phone: Phone:
Title: Title:
Name: Name:
Possition: Possition:
Email: Email:
Phone: Phone:
Organization:
Address:
City:
Fax: Phone:
Signature: Date:
This booking is invalid without signature
PRICES
Delegate package + VAT Solution Provider and Vendor + VAT Online documentation
1,699€ 1,999€ 499€
Card No:
Card Holder:
Expiration:
Billing Address:
City: Postcode:
CVV:
If you haven’t recieved a registration corfimation within 48 hours of registering, please call +420 210 022 063
daniel.holm@globalbsg.com Phone: +420 210 022 063 Fax your booking to: + 420 234 256 231
Payment Terms: Full payment is required within five (5) business days of the return of the signed registration form. There are no refunds given under any circumstances. Non-payment or non-attendance does not constitute cancel-
A confirmation letter and invoice will be sent on receipt of your booking. If you do not receive a letter outlining lation. The booking fee does not include accommodation or travel costs; these are the responsibility of the Dele-
details two weeks prior to the event, please contact the Conference Director at Business Solution Group. Cancel- gate. It may be necessary for reasons beyond the control of Business Solution Group to alter the content, timings
lations: Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must or venue. Business Solution Group is not responsible for any loss or damage as a result of a substitution, alteration,
be received in writing no less than fourteen (14) days prior to the event. You would then be issued a credit note or cancellation/ postponement of an event. Business Solution Group shall assume no liability whatsoever in the
for 100% of the contract fee paid to be used at another Business Solution Group event, which must occur within event this conference is cancelled, rescheduled or postponed due to a fortuitous event, Act of God, unforeseen
one year from the date of issuance. In the event that Business Solution Group cancels or postpones an event for occurrence or any other event that renders performance of this conference impracticable, illegal or impossible.
any reason, the delegate will receive a credit note for 100% of the contract fee paid. In the event that Business Please note that while speakers and topics were confirmed at the time of publishing, circumstances beyond the
Solution Group postpones control of Business Solution Group may necessitate substitutions, alterations or cancellations of the speakers and/
an event for any reason and the delegate is unable or unwilling to attend on the rescheduled date, the delegate or topics. As such, Business Solution Group reserves the right to alter or modify the advertised speakers and/or
will receive a credit note for 100% of the contract fee paid. You may use this credit for another Business Solution topics if necessary without any liability to you whatsoever.
Group event, which must occur within one year from the date of cancellation or postponement. Except as specified
above, no credits will be issued for cancellations. The full T&C is available on our website - www.globalbsg.com
Politickych Veznu 912/10,
Nove Mesto. 110 000 Praque 1,
Czech Republic
info@globalbsg.com